Systematic Financial Management LP reduced its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 56.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 129,032 shares of the medical instruments supplier’s stock after selling 170,275 shares during the period. Systematic Financial Management LP owned 0.35% of AngioDynamics worth $2,226,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Crossmark Global Holdings Inc. acquired a new stake in shares of AngioDynamics in the 4th quarter valued at $172,000. Aperio Group LLC acquired a new stake in shares of AngioDynamics during the first quarter worth $192,000. Teacher Retirement System of Texas acquired a new stake in shares of AngioDynamics during the fourth quarter worth $201,000. Port Capital LLC acquired a new stake in shares of AngioDynamics during the first quarter worth $213,000. Finally, Bailard Inc. acquired a new stake in shares of AngioDynamics during the first quarter worth $278,000. 97.62% of the stock is owned by institutional investors.
Shares of AngioDynamics opened at $20.54 on Friday, Marketbeat.com reports. The company has a quick ratio of 1.84, a current ratio of 2.88 and a debt-to-equity ratio of 0.16. AngioDynamics, Inc. has a 12 month low of $14.97 and a 12 month high of $20.71. The firm has a market cap of $749.71 million, a P/E ratio of 28.14, a P/E/G ratio of 1.84 and a beta of 1.01.
AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Thursday, March 29th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.05. AngioDynamics had a return on equity of 5.11% and a net margin of 0.97%. The firm had revenue of $83.85 million during the quarter, compared to analysts’ expectations of $86.13 million. equities research analysts anticipate that AngioDynamics, Inc. will post 0.74 earnings per share for the current fiscal year.
A number of equities research analysts recently commented on ANGO shares. BidaskClub raised AngioDynamics from a “sell” rating to a “hold” rating in a research note on Thursday, February 22nd. UBS raised AngioDynamics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, April 3rd. TheStreet raised AngioDynamics from a “c” rating to a “b-” rating in a research note on Monday, April 16th. Raymond James raised AngioDynamics from a “market perform” rating to an “outperform” rating and set a $16.33 price objective for the company in a research note on Tuesday, April 3rd. Finally, Canaccord Genuity lifted their price objective on AngioDynamics from $16.50 to $17.00 and gave the stock a “hold” rating in a research note on Monday, April 2nd. Five investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $17.87.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities.
Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.